The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $19.75

Today's change+0.47 +2.44%
Updated May 23 4:00 PM EDT. Delayed by at least 15 minutes.
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $19.75

Today's change+0.47 +2.44%
Updated May 23 4:00 PM EDT. Delayed by at least 15 minutes.

Nektar Therapeutics crosses above 50-day moving average

Nektar Therapeutics closed up sharply Tuesday, rallying (U.S.)$0.47 or 2.44% to (U.S.)$19.75 and crossing above its 50-day moving average. Over the last five days, shares have gained 1.07% and 60.96% year to date. Shares have outperformed the S&P 500 by 23.26% during the last year.

Key company metrics

  • Open(U.S.) $19.22
  • Previous close(U.S.) $19.28
  • High(U.S.) $19.77
  • Low(U.S.) $18.84
  • Bid / Ask(U.S.) $15.19 / (U.S.) $22.80
  • YTD % change+60.96%
  • Volume1,213,057
  • Average volume (10-day)1,544,978
  • Average volume (1-month)1,677,288
  • Average volume (3-month)1,863,766
  • 52-week range(U.S.) $11.41 to (U.S.) $24.88
  • Beta1.57
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.37
Updated May 23 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-150.74%

Although this company's net profit margin is negative, it is above the industry average and implies that Nektar Therapeutics is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.12%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue25373633
Total other revenue--------
Total revenue25373633
Gross profit19312925
Total cost of revenue6778
Total operating expense79706971
Selling / general / administrative12131011
Research & development61505252
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--0----
Other operating expenses, total--------
Operating income-54-32-33-38
Interest income (expense), net non-operating-10-10-11-11
Gain (loss) on sale of assets--------
Other--------
Income before tax-64-42-43-48
Income after tax-64-42-43-49
Income tax, total0000
Net income-64-42-43-49
Total adjustments to net income--------
Net income before extra. items-64-42-43-49
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-64-42-43-49
Inc. avail. to common incl. extra. items-64-42-43-49
Diluted net income-64-42-43-49
Dilution adjustment--------
Diluted weighted average shares154149137136
Diluted EPS excluding extraordinary itemsvalue per share-0.42-0.28-0.32-0.36
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.42-0.28-0.32-0.36